

# Baseline Characteristics in Patients with Atopic Dermatitis from the North American Prospective Observational Study of Lebrikizumab (ADjoy)

Jennifer Soung<sup>1</sup>, Vimal H. Prajapati<sup>2</sup>, Jill Waibel<sup>3</sup>, Lara Wine Lee<sup>4</sup>, Lawrence F. Eichenfield<sup>5</sup>, Abel Jarell<sup>6</sup>, Alexa Hetzel<sup>7</sup>, Gaia Gallo<sup>8</sup>, Evangeline Pierce<sup>8</sup>, Roberto Marrero<sup>8</sup>, Amy Larkin<sup>8</sup>, Michael Behling<sup>9</sup>, Shawn G. Kwatra<sup>10</sup>

<sup>1</sup>Southern California Dermatology, Santa Ana, CA, USA; <sup>2</sup>Dermatology Research Institute, Skin Health & Wellness Centre, Probitry Medical Research, and University of Calgary, Canada; <sup>3</sup>Baptist Hospital and Miami Dermatology and Laser Institute, Miami, FL, USA; <sup>4</sup>Medical University of South Carolina, Charleston, SC, USA; <sup>5</sup>University of California, San Diego School of Medicine, CA, USA; <sup>6</sup>Northeast Dermatology Associates aIICUTIS Research, Portsmouth, NH, USA; <sup>7</sup>Schweiger Dermatology Group, East Windsor, NJ, USA; <sup>8</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>9</sup>Syneos Health, Morrisville, NC, USA; <sup>10</sup>University of Maryland School of Medicine, MD, USA

Sponsored by Eli Lilly and Company

## BACKGROUND & OBJECTIVE

- Lebrikizumab demonstrated long-term efficacy and safety in Phase 3 clinical trials in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD).<sup>1,2</sup>
- Real-world data on lebrikizumab's effectiveness and treatment persistence are essential to describe its use in routine clinical practice.
- To report the preliminary baseline patient demographics and disease characteristics in moderate-to-severe AD patients from the real-world study ADjoy.



## CONCLUSION

- This is the first disclosure of real-life patients with AD initiating lebrikizumab in the United States and Canada.
- This interim analysis shows a heterogeneous, uncontrolled AD population initiating lebrikizumab, highlighting an unmet need in patients' prior treatments to control disease activity.

Winter Clinical Dermatology Conference – Hawaii; 16-21 January 2026; Maui, USA

## KEY RESULTS: Clinical Characteristics Indicate the Majority of Participants had Moderate-to-Severe Atopic Dermatitis at Baseline

- The majority of participants had baseline characteristics of moderate or severe disease according to IGA, EASI, and PGI-S-AD scores.
- Participants had uncontrolled disease at baseline according to ADCT scores.



**PGI-S-AD:** 1: no symptoms; 2: very mild; 3: mild; 4: moderate; 5: severe. Missing: n=12.  
**Investigator's Global Assessment:** 0: Clear; 1: Almost clear; 2: Mild; 3: Moderate; 4: Severe.  
**Eczema Area and Severity Index:** 0-1: clear/almost clear; >1-7: mild; >7-21: moderate; >21-50: severe; >50-72: very severe.  
**ADCT:** Evaluates 6 symptoms and effects associated with AD over the previous week: overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. Scores range from 0 (no problem) to 4 (worst), total score ranges from 0-24, and a score of ≥7 indicates uncontrolled disease. Missing: n=12.  
**DLQI:** Consist of 10 items designed to assess the impact of skin disease on a patient's quality of life. Each question addresses different domains such as symptoms and feelings, daily activities, leisure, work or school, personal relationships, and treatment. Patients respond using a four-point scale: "Not at all" (0), "A little" (1), "A lot" (2), and "Very much" (3). Missing: n=16.  
**Pruritus NRS:** The Peak Pruritus NRS is a single item, 11-point self-reported item designed to measure peak pruritus, or "worst" itch, over the previous 24 hours based on a scale of 0 to 10, with 0: "no itch", 1-3: Mild pruritus, 4-6: moderate pruritic, 7-9: severe pruritic, 10: worst itch imaginable. Missing: n=14.

All values are shown as median (IQR), unless indicated otherwise.  
 Abbreviations: AD: Atopic Dermatitis; ADCT: Atopic Dermatitis Control Tool; DLQI: Dermatology Life Quality Index; EASI: Eczema Area and Severity Index; IQR: interquartile range; IGA: Investigator's Global Assessment; NRS: Numeric Rating Scale; Patient Global Impression of Severity-AD scores.

## METHODS

- ADjoy, a 104-week, prospective, Phase 4, multicenter, single-arm observational study, reflects real-world lebrikizumab treatment in participants with moderate-to-severe AD within clinical practice settings.
- This descriptive analysis reports baseline data from the first interim analysis (N=134) of the ongoing ADjoy study.
- Participants aged ≥12 years will be recruited across 60 sites in the United States and Canada.
- All data is reported as observed; no imputations of missing data were conducted.

### Inclusion criteria

- Patients aged ≥12 years, weighing ≥40kg.
- Physician confirmed diagnosis with moderate-to-severe AD at least 6 months prior to baseline.
- Eligible for treatment with lebrikizumab according to local labeling and the study investigator's decision.

### Exclusion criteria


- Previous exposure to lebrikizumab.
- Unable to initiate lebrikizumab within 90 days.

Abbreviations: AD: Atopic Dermatitis.

**Disclosures:** JS: Speaker, consultant, and/or investigator for: AbbVie, Alumis, Aslan, Amgen, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly (Lilly), Galderma, Incyte, Johnson & Johnson, KoBio Labs, LEO, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and UCB. **VHP:** Advisor, consultant, and/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipter, CorEvitas, Eczema Society of Canada, Lilly, Galderma, GlaxoSmithKline, Homecan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, Kenvue, Knight Therapeutics, LEO Pharma, Medexus, Nia Health, Novartis, Organon, Paladin, PediaPharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; Investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Lilly, Galderma, Incyte, J&J Innovative Medicine, Janssen, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; Received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Target RWE, T-Rex, and UCB. **AJ:** Scientific adviser or clinical study investigator for: AbbVie, Asana BioSciences, Bristol Myers Squibb, Castle BioSciences, Celgene, Dermira, Lilly and Company, Galderma, Genentech/Roche, GlaxoSmithKline, LEO Pharma, Novartis, Pfizer, Purdue Pharma, Regeneron, Sanofi Genzyme, Sienna Biopharmaceuticals, Sun Pharma, and UCB Pharma; Speaker for: Castle BioSciences, Lilly, Novartis, Regeneron, and Sanofi Genzyme. **AH:** Honoraria/speaker's bureau: Lilly, J&J, UCB, Incyte, Sanofi/Regeneron, Abbvie, BMS, Pelthos, Arcutis, Pfizer; Travel support and Leadership or fiduciary role in other board, society, committee or advocacy group: Dermatology Education Foundation; Participation in advisory board: Lilly, J&J, Novartis, Amgen, Abbvie, BMS, Pfizer, Journey; Other financial or non-financial interests (Clinical trial): Amgen, Leo, J&J, Sanofi/Regeneron, Dermavant, Takeda, Menlo, Abbvie, Lilly, Arcutis, BMS, GG, EP, RM, and AL: Employees and stockholders of Lilly. **MB:** Employee, Syneos Health, a contractual employee of Lilly. **SGK:** Advisory board member or consultant for: AbbVie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Bristol Myers Squibb, Cara Therapeutics, Castle BioSciences, Dermavant, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi; investigator for Galderma, Incyte, Pfizer, and Sanofi.


Copyright ©2026 Eli Lilly and Company. All rights reserved.

## Clinical characteristics (N=134)



All values are shown as median (IQR), unless indicated otherwise.  
 Abbreviations: AD: Atopic Dermatitis; ADCT: Atopic Dermatitis Control Tool; BMI: Body Mass Index; BSA: body surface area; DLQI: Dermatology Life Quality Index; IQR: interquartile range; NRS: Numeric Rating Scale.


## Commonly Affected Areas and Associated Comorbidities



AD-associated comorbidities	Patients N=107
Seasonal allergies	57 (43.5)
Asthma	44 (33.3)
Allergic Rhinitis	30 (23.1)
Food allergies	24 (18.5)
Conjunctivitis <sup>a</sup>	17 (13.1)

All values are in n (%). <sup>a</sup>Medical history of conjunctivitis.  
 Abbreviations: AD: Atopic Dermatitis.

## Demographic characteristics (N=134)



All values are shown as n (%), unless indicated otherwise.  
 Abbreviations: IQR: interquartile range.

### References:

- Silverberg IJ, et al. N Engl J Med. 2023;388(12):1080-1091.
- Simpson EL, et al. JAMA Dermatol. 2023;59(2):182-191.

**Acknowledgments:** The authors would like to thank Niamh Wiley and Pooja Sagar, employees of Lilly, for providing medical writing support.



Scan the QR code for a list of all Lilly content presented at the congress.  
 Other company and product names are trademarks of their respective owners.